


Continuation of International Application Number PCT/EP02/01181
Preliminary Amendment Dated August 5, 2003

Amendment to the Abstract:

After the claims, please insert the Abstract on the following page. The Abstract is the same as that published in the priority document PCT WO 02/062830 A2 (International Application No. PCT/EP02/01181).

-- ABSTRACT



(I)

The invention relates to the use of specific tripeptides for the treatment of neurodegenerative diseases. The tripeptide derivatives satisfy the following formula (I): wherein X represents OH , $(C_{1-5})alkoxy$, NH_2 , $NH-C_{1-5}-alkyl$, $N(C_{1-5} alkyl)_2$; R_1 is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile; R_2 is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn; R_3 and R_4 independently represent H , OH , $(C_{1-5})alkyl$, or $(C_{1-5})alkoxy$, provided that R_3 and R_4 are not both OH or $(C_{1-5})alkoxy$; R_5 represents H , OH , $(C_{1-5})alkyl$ or $(C_{1-5})alkoxy$; and wherein R_0 preferably represents a cinnamoyl residue; or pharmaceutically acceptable salts thereof. --